Residual Mitral Regurgitation as a Long-Term Predictor of Mortality After Mitral TEER.

Authors

Dennis Rottländer, Taoufik Ouarrak, Jörg Hausleiter, Thomas Schmitz, Alexander Bufe, Melchior Seyfarth, Harald Beucher, Steffen Schneider, Peter Boekstegers, MITRA-PRO Investigators

Published in

JACC. Cardiovascular interventions. Volume 19. Issue 18. Pages 2474-2486. Sep 28, 2026.

Abstract

The MITRA-PRO registry revealed residual mitral regurgitation (MR) as an important predictor of 1-year and 3-year mortality following mitral transcatheter edge-to-edge repair (M-TEER).
The 5-year follow-up of the MITRA-PRO registry (N = 1,491) aimed to assess the impact of residual MR on 5-year mortality. Furthermore, time-dependent predictors of mortality after M-TEER should be assessed.
Patients with a MitraScore of ≤3 were classified as patients with mild residual MR after M-TEER, while a MitraScore of ≥4 was defined as relevant residual MR. Adjusted HRs were calculated for multivariate analysis of time-dependent predictors.
Five-year mortality was significantly lower in patients with mild or less residual MR compared with patients with more than mild residual MR (MitraScore ≤3 group: 55.1% vs MitraScore ≥4 group: 67.7%). The relationship between intraprocedural MitraScore after M-TEER and mortality was almost linear. In patients with degenerative MR, 5-year mortality was 53.1% in the MitraScore ≤3 group and 73.2% in the MitraScore ≥4 group. Regarding functional MR, the corresponding 5-year mortality rates were 55.0% and 64.6%. Mortality predictors after M-TEER were time dependent: Early risk was driven by advanced disease and procedural factors, whereas residual MR became prognostic after 30 days and remained associated with excess long-term mortality.
Residual MR assessed by intraprocedural MitraScore after M-TEER independently predicts 5-year mortality. This finding underscores the importance of achieving optimal MR reduction during M-TEER and supports quantitative multimodal intraprocedural assessment to guide strategy and improve long-term outcomes.

PMID:
42805718
Bibliographic data and abstract were imported from PubMed on 29 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.